Home › Breast Cancer › NCT05406232

Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer

Breast Radiation-induced Immunologic Genomic Hypofractionated Temporal Radiation Alterations DNA Damage (BRIGHT-RAD) Study.

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Patients \>= 18 years of age with biopsy proven invasive breast cancer
* Breast cancer that appears to be superficially accessible to a tumor punch biopsy
* Patients thought to derive clinical benefit from palliative RT to the breast/chestwall
* In discussions with the medical oncologist, if clinically reasonable, systemic therapy will be held during RT

Exclusion Criteria:

* A history of prior radiation to the area requiring radiation for which the attending physician believes reirradiation could not be safely delivered
* Pregnancy
* Active usage of anticoagulant medications that are considered to pose an increased risk of tumor punch biopsies
* Receipt of immunotherapy or chemotherapy 7 days prior to start of RT

About the study

This study assesses changes to the immune cells following hypofractionated radiation-induced DNA damage in breast cancer patients. Radiation therapy may cause immune cells to enter tumors and target cancer cells. The goal of this study is to measure the change in the level of immune cells in the tumor before and after radiation therapy.

What is being tested

• Biopsy (procedure)
• Biospecimen Collection (procedure)
• Radiation Therapy (radiation)

Sponsor: M.D. Anderson Cancer Center · Participants: 36 · Started: Sep 15, 2023

Contact the study team

• Simona F Shaitelman, MD · Phone: (713) 563-8491

Official record on ClinicalTrials.gov — NCT05406232

Locations in the U.S.

Conditions

• Breast Cancer

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.